Backed By Science
Clinical Papers From Top Doctors & Universities
Wegovy (semaglutide): a new weight loss drug for chronic weight management
Wegovy (semaglutide) is not only superior at reducing body weight compared with other antidiabetic drugs, but it is also cardioprotective. Another significant benefit of Semaglutide is that it can be used for long term management of weight. With the recent approval of Wegovy, we could expect improvement in patients’ weight loss-related outcomes and quality of life.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestylee intervention was associated with sustained, clinically relevant reduction in body weight.
Tirzepatide Once Weekly for the Treatment of Obesity
In the present trial, all three doses of once-weekly tirzepatide demonstrated substantial and sustained weight reduction in adults with obesity.
Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects
In summary, proteins found to change after one week of increased GH and IGF-1 secretion induced by treatment with CJC-1295 were ApoA1, TTR, beta-hemoglobin, two albumin fragments and an immunoglobulin fragment.
